TFF Pharmaceuticals (NASDAQ:TFFP – Get Rating) had its price objective trimmed by HC Wainwright from $22.00 to $4.00 in a research note released on Thursday morning, The Fly reports.
Separately, Jonestrading assumed coverage on TFF Pharmaceuticals in a report on Wednesday, March 22nd. They set a buy rating and a $7.00 target price for the company.
TFF Pharmaceuticals Stock Down 7.1 %
Shares of NASDAQ TFFP opened at $0.55 on Thursday. TFF Pharmaceuticals has a 1-year low of $0.48 and a 1-year high of $6.73. The business’s fifty day moving average price is $0.66 and its two-hundred day moving average price is $0.89.
Insider Buying and Selling
Institutional Investors Weigh In On TFF Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in TFFP. UBS Group AG grew its holdings in TFF Pharmaceuticals by 13.8% in the 1st quarter. UBS Group AG now owns 129,780 shares of the company’s stock valued at $89,000 after buying an additional 15,709 shares during the last quarter. Sigma Planning Corp increased its stake in shares of TFF Pharmaceuticals by 53.8% in the 1st quarter. Sigma Planning Corp now owns 155,191 shares of the company’s stock valued at $106,000 after buying an additional 54,300 shares during the period. Gagnon Securities LLC increased its stake in shares of TFF Pharmaceuticals by 255.3% in the 1st quarter. Gagnon Securities LLC now owns 221,207 shares of the company’s stock valued at $152,000 after buying an additional 158,943 shares during the period. AIGH Capital Management LLC acquired a new stake in shares of TFF Pharmaceuticals in the 4th quarter valued at $1,826,000. Finally, DRW Securities LLC acquired a new stake in shares of TFF Pharmaceuticals in the 4th quarter valued at $1,050,000. 16.46% of the stock is owned by hedge funds and other institutional investors.
TFF Pharmaceuticals Company Profile
TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.
- Get a free copy of the StockNews.com research report on TFF Pharmaceuticals (TFFP)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.